about
Association of the cyclin-dependent kinases and 14-3-3 sigma negatively regulates cell cycle progressionCOP9 signalosome subunit 6 stabilizes COP1, which functions as an E3 ubiquitin ligase for 14-3-3σCancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapiesERK2-Dependent Phosphorylation of CSN6 Is Critical in Colorectal Cancer DevelopmentTumor suppressor ARF inhibits HER-2/neu-mediated oncogenic growthConstitutively active FOXO4 inhibits Akt activity, regulates p27 Kip1 stability, and suppresses HER2-mediated tumorigenicityMulti-gene fluorescence in situ hybridization to detect cell cycle gene copy number aberrations in young breast cancer patients.Effects of obesity on transcriptomic changes and cancer hallmarks in estrogen receptor-positive breast cancer.The association of diabetes and anti-diabetic medications with clinical outcomes in multiple myelomaCSN6 drives carcinogenesis by positively regulating Myc stability.TRIM24 links glucose metabolism with transformation of human mammary epithelial cellsMaintenance Therapy Containing Metformin and/or Zyflamend for Advanced Prostate Cancer: A Case SeriesThiazolidinediones and metformin associated with improved survival of diabetic prostate cancer patients.Circadian Clock Gene CRY2 Degradation Is Involved in Chemoresistance of Colorectal Cancer.CSN6 deregulation impairs genome integrity in a COP1-dependent pathway14-3-3sigma exerts tumor-suppressor activity mediated by regulation of COP1 stability.Metformin and thiazolidinediones are associated with improved breast cancer-specific survival of diabetic women with HER2+ breast cancer.Hepatocyte Growth Factor/cMET Pathway Activation Enhances Cancer Hallmarks in Adrenocortical Carcinoma.Regulating the stability and localization of CDK inhibitor p27(Kip1) via CSN6-COP1 axis.COP1 enhances ubiquitin-mediated degradation of p27Kip1 to promote cancer cell growth.p53 negatively regulates Aurora A via both transcriptional and posttranslational regulation.COP9 signalosome subunit 6 (CSN6) regulates E6AP/UBE3A in cervical cancer.FBXW7 is involved in Aurora B degradation.HER2-Akt signaling in regulating COP9 signalsome subunit 6 and p53Regulation of the p53-MDM2 pathway by 14-3-3 sigma and other proteins.Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer14-3-3 sigma positively regulates p53 and suppresses tumor growth.CSN6 positively regulates c-Jun in a MEKK1-dependent manner.Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937.Obesity-associated NLRC4 inflammasome activation drives breast cancer progression.Aurora-B kinase inhibitors for cancer chemotherapy.The brain-specific activator p35 allows Cdk5 to escape inhibition by p27Kip1 in neurons.Roles of COP9 signalosome in cancer.A hypoxia-responsive TRAF6-ATM-H2AX signalling axis promotes HIF1α activation, tumorigenesis and metastasis.Pim-1 plays a pivotal role in hypoxia-induced chemoresistance.Roles for CSN5 in control of p53/MDM2 activities.Negative cell cycle regulator 14-3-3sigma stabilizes p27 Kip1 by inhibiting the activity of PKB/Akt.Modified p27 Kip1 is efficient in suppressing HER2-mediated tumorigenicity.Correlation of p27 protein expression with HER-2/neu expression in breast cancer.CSN6-COP1 axis in cancer
P50
Q22253912-8E952F45-8E0A-4341-9085-4ECAA09511BDQ24304964-B0F1F5BE-CEE4-48EA-BDCE-EC5F7ABD7926Q26823118-D39878ED-C3F6-4FCD-A3C2-B2773932DF69Q28115416-27E46D09-16F5-4EAF-B523-1981C3003042Q28273757-A24655FB-0C2A-4FE5-AC70-BEB76D71F80BQ28305487-010FE664-01D6-4447-B3D4-360387ED639CQ33728390-1C5A4B20-4088-4842-A6E7-AD0ABA763D66Q33947907-09C58820-C580-449A-8191-7B72D63EEB20Q33994341-F8FEBBBF-65A3-4734-BE3A-14BCBEC59F85Q34523341-78306A49-2742-4AA7-B485-0588ADF431D6Q35209056-DCCDC3B6-20FA-492F-9064-590435446693Q35226909-9163A509-114D-48FF-99CC-5AFEA1CB5557Q35565610-D70793C6-358D-4C8A-AA25-CDBC77AA881BQ35691235-2B94B7A1-DDED-463F-9233-FB2B0FBB23B1Q35828435-A5F12CB4-860B-4026-9A27-29F65D687C2BQ35979769-64A644BE-8FBA-4C5A-8CC4-D1CE1A40C232Q36070998-828D568A-7E1C-4AA6-84FF-38201A9B7829Q36118082-9D1707A4-AF5A-4E57-969F-D055DFB16521Q36183877-E439B28B-EBDE-4ECC-95BA-3EDBA800B0B3Q36260630-35DF9184-AFC4-4C0F-BC46-1E50A0F46AF1Q36304176-A61BADD7-DA9B-4928-BC65-72382D607C82Q36413974-AFB2D87A-660A-42DC-A1B4-AFBEC6A841FBQ36426514-5892EFF4-1ED3-41E3-AA54-9651603976FBQ36472246-3F782A63-55F4-430D-A8F8-27F79774E725Q36477042-8856F287-1BD3-4BCC-B059-1BC1305D2C14Q36508067-16A6B445-E0CA-4F6E-B48A-21D42879F172Q36549508-703A5EA6-82AC-49C1-9163-5DFFA8C2802CQ36780798-FA9CB2A3-9DD6-45A1-832B-C54FFACBEDBDQ36791514-C146D915-E0C7-466C-8986-D815281E930DQ37330542-2D0BBEE0-04DB-4F87-BA4F-AED2BC734E21Q37347616-5C3ED104-9F5F-4927-9135-614CE35D5ABDQ37647121-090A32A0-B399-4F14-B8C8-7E9A4C869D08Q37923711-87134ACE-AE6E-4249-843B-FB99F88DFEFAQ38727581-34DB6283-D8D8-4EC8-8B6F-9AE17A92B846Q39844632-8CFAAD37-9C75-45DA-9F12-09E656AA6E5FQ40078645-3359CE2B-829F-488F-8A38-C85B5861E0A2Q40305915-F6C72F4A-79FA-42BC-B8C9-4A35425AB311Q40338218-A2C6EBA7-45EF-46F3-BE78-36F09B742839Q40713599-37A63E77-C074-4E0D-9E16-F66B69EBCA75Q42703336-389EEF64-F3C8-4884-9035-D393606CE93E
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mong-Hong Lee
@ast
Mong-Hong Lee
@en
Mong-Hong Lee
@es
Mong-Hong Lee
@nl
type
label
Mong-Hong Lee
@ast
Mong-Hong Lee
@en
Mong-Hong Lee
@es
Mong-Hong Lee
@nl
prefLabel
Mong-Hong Lee
@ast
Mong-Hong Lee
@en
Mong-Hong Lee
@es
Mong-Hong Lee
@nl
P106
P1153
35278917200
P31
P496
0000-0001-8675-8215